A team of researchers from the European Institute of Oncology and the Politecnico di Milano developed the novel “gut-on-a-chip”: a miniature model of the human intestine on a chip-sized device capable of reproducing the main features of intestinal inflammation as a biomarker for response to immune checkpoint inhibitors in patients with melanoma.
Health Professionals
Hargadon Publishes Cancer Research
Trinkle Professor of Biology Kristian M. Hargadon ’01 and two alumni co-authors published research on anti-tumor immune dysfunction in Cancer Reports.
Packing lipid nanoparticles with tumor proteins to boost cancer vaccine potency
The concept of using vaccines to treat cancers has been around for several decades. A vaccine was first approved for prostate cancer in 2010, and another was approved in 2015 for melanoma. Since then, many therapeutic—as opposed to preventive—cancer vaccines have been in development, but none are approved. One hurdle is the difficulty in finding antigens in tumors that look foreign enough to trigger an immune response.
Understanding Biomarkers in Early-Stage Melanoma
Hello, everybody. My name is Teresa Amaral, and today I’m here to talk to you about biomarkers. I would like to frame this in relation to the treatment of patients with melanoma, especially early-stage melanoma. Do we have any biomarkers that we could use in the early stage of melanoma?